FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022641210> ?p ?o ?g. }

• W2022641210 endingPage "389" @default.
• W2022641210 startingPage "383" @default.
• W2022641210 abstract "What is known and objective The elderly are at increased risk of adverse effects resulting from drug interactions due to decreased drug clearance and polypharmacy. This study examines the prevalence of the co-administration of clinically relevant cytochrome P450 (CYP) enzyme inhibitors with drugs that are substrates for these enzymes, in the community-dwelling elderly in Australia. Methods Participants aged 75 years or older (n = 1045) were recruited via their general practitioners at four Australian sites (Newcastle, Sydney, Melbourne and Adelaide). A research nurse visited the home of each patient to compile a list of all prescription medications (including doses) currently used by the patient, and to complete assessments for depression, quality of life and cognitive status. The medication data were searched for the co-prescription of clinically relevant CYP inhibitor and corresponding substrate drugs. Results and discussion Potentially inappropriate CYP inhibitor–substrate combinations were found in 6·2% (65/1045) of patients. These patients were on significantly more medications (6·1 ± 3·0 vs. 3·9 ± 2·5; P = 0·001) and had a significantly lower physical quality of life (P = 0·047) than those who were not on any CYP inhibitor–substrate combinations. The most commonly prescribed inhibitor–substrate combinations involved the CYP 3A4 inhibitors, diltiazem and verapamil, with the substrates simvastatin or atorvastatin. Only 1 of 41 patients on a CYP3A4 inhibitor and a statin was prescribed a non-CYP 3A4 metabolized statin. Metoprolol was another substrate commonly co-prescribed with a CYP2D6 inhibitor. In many cases, the risks and benefits of potential interactions may have been considered by the GP as the prescribed doses of both the inhibitor and substrate were relatively low. There were, however, some notable exceptions, also involving the substrates simvastatin, atorvastatin and metoprolol. There were no GP factors that were associated with co-prescription of CYP inhibitors and substrates. What is new and conclusion There is not a particular GP demographic that should be targeted for education regarding CYP interactions, but a focus on particular medications such as the statins may reduce the potential for clinically significant drug–drug interactions. As CYP drug–drug interactions are more common in patients on higher number of medications, particular vigilance is required at the time of prescribing and dispensing medications for elderly patients with multiple conditions." @default.
• W2022641210 created "2016-06-24" @default.
• W2022641210 creator A5008365304 @default.
• W2022641210 creator A5020170490 @default.
• W2022641210 creator A5032748191 @default.
• W2022641210 creator A5033818609 @default.
• W2022641210 creator A5039039691 @default.
• W2022641210 creator A5069286040 @default.
• W2022641210 creator A5070452814 @default.
• W2022641210 date "2014-04-07" @default.
• W2022641210 modified "2023-10-16" @default.
• W2022641210 title "The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians" @default.
• W2022641210 cites W1483491932 @default.
• W2022641210 cites W1602209075 @default.
• W2022641210 cites W176732531 @default.
• W2022641210 cites W1895213789 @default.
• W2022641210 cites W1910554438 @default.
• W2022641210 cites W1969879564 @default.
• W2022641210 cites W1975031562 @default.
• W2022641210 cites W1981046943 @default.
• W2022641210 cites W1995878005 @default.
• W2022641210 cites W1996289357 @default.
• W2022641210 cites W1996830334 @default.
• W2022641210 cites W199719405 @default.
• W2022641210 cites W2002044083 @default.
• W2022641210 cites W2002702566 @default.
• W2022641210 cites W2005328285 @default.
• W2022641210 cites W2016749234 @default.
• W2022641210 cites W2021354489 @default.
• W2022641210 cites W2028566416 @default.
• W2022641210 cites W2034523900 @default.
• W2022641210 cites W2040982838 @default.
• W2022641210 cites W2043249607 @default.
• W2022641210 cites W2043506895 @default.
• W2022641210 cites W2051350612 @default.
• W2022641210 cites W2060477105 @default.
• W2022641210 cites W2080857368 @default.
• W2022641210 cites W2080995941 @default.
• W2022641210 cites W2108129761 @default.
• W2022641210 cites W2110171695 @default.
• W2022641210 cites W2115763439 @default.
• W2022641210 cites W2116707335 @default.
• W2022641210 cites W2138332753 @default.
• W2022641210 cites W2148547630 @default.
• W2022641210 doi "https://doi.org/10.1111/jcpt.12163" @default.
• W2022641210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24702306" @default.
• W2022641210 hasPublicationYear "2014" @default.
• W2022641210 type Work @default.
• W2022641210 sameAs 2022641210 @default.
• W2022641210 citedByCount "15" @default.
• W2022641210 countsByYear W20226412102015 @default.
• W2022641210 countsByYear W20226412102016 @default.
• W2022641210 countsByYear W20226412102017 @default.
• W2022641210 countsByYear W20226412102018 @default.
• W2022641210 countsByYear W20226412102019 @default.
• W2022641210 countsByYear W20226412102020 @default.
• W2022641210 countsByYear W20226412102023 @default.
• W2022641210 crossrefType "journal-article" @default.
• W2022641210 hasAuthorship W2022641210A5008365304 @default.
• W2022641210 hasAuthorship W2022641210A5020170490 @default.
• W2022641210 hasAuthorship W2022641210A5032748191 @default.
• W2022641210 hasAuthorship W2022641210A5033818609 @default.
• W2022641210 hasAuthorship W2022641210A5039039691 @default.
• W2022641210 hasAuthorship W2022641210A5069286040 @default.
• W2022641210 hasAuthorship W2022641210A5070452814 @default.
• W2022641210 hasBestOaLocation W20226412101 @default.
• W2022641210 hasConcept C126322002 @default.
• W2022641210 hasConcept C197934379 @default.
• W2022641210 hasConcept C2426938 @default.
• W2022641210 hasConcept C2776839432 @default.
• W2022641210 hasConcept C2777482532 @default.
• W2022641210 hasConcept C2780035454 @default.
• W2022641210 hasConcept C33664856 @default.
• W2022641210 hasConcept C36434225 @default.
• W2022641210 hasConcept C526171541 @default.
• W2022641210 hasConcept C62231903 @default.
• W2022641210 hasConcept C71924100 @default.
• W2022641210 hasConcept C97320921 @default.
• W2022641210 hasConcept C98274493 @default.
• W2022641210 hasConceptScore W2022641210C126322002 @default.
• W2022641210 hasConceptScore W2022641210C197934379 @default.
• W2022641210 hasConceptScore W2022641210C2426938 @default.
• W2022641210 hasConceptScore W2022641210C2776839432 @default.
• W2022641210 hasConceptScore W2022641210C2777482532 @default.
• W2022641210 hasConceptScore W2022641210C2780035454 @default.
• W2022641210 hasConceptScore W2022641210C33664856 @default.
• W2022641210 hasConceptScore W2022641210C36434225 @default.
• W2022641210 hasConceptScore W2022641210C526171541 @default.
• W2022641210 hasConceptScore W2022641210C62231903 @default.
• W2022641210 hasConceptScore W2022641210C71924100 @default.
• W2022641210 hasConceptScore W2022641210C97320921 @default.
• W2022641210 hasConceptScore W2022641210C98274493 @default.
• W2022641210 hasIssue "4" @default.
• W2022641210 hasLocation W20226412101 @default.
• W2022641210 hasLocation W20226412102 @default.
• W2022641210 hasOpenAccess W2022641210 @default.
• W2022641210 hasPrimaryLocation W20226412101 @default.
• W2022641210 hasRelatedWork W1581747141 @default.

• next